Clinical Trial Update: Treatment With Nab-paclitaxel in Cutaneous SCC [Phase 2]

View source ↗

Summary

A phase 2 trial of nab-paclitaxel for cutaneous squamous cell carcinoma was terminated and results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Cutaneous Squamous Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2017-10-25